Welcome to our dedicated page for Burning Rock Biotech news (Ticker: BNR), a resource for investors and traders seeking the latest updates and insights on Burning Rock Biotech stock.
Burning Rock Biotech Limited (BNR) reports developments in next-generation sequencing technology for precision oncology. Its news commonly covers financial results, Form 20-F annual reporting, annual general meeting actions, ADS-related ownership announcements, and clinical or regulatory updates for NGS assays used in therapy selection, MRD assessment, companion diagnostics and cancer early detection.
Company updates reference products and technologies such as OncoScreen, CanCatch and ELSA-seq, including study publications, patent grants and companion-diagnostic approvals connected to precision oncology testing.
Burning Rock Biotech Limited (NASDAQ: BNR) has announced its inclusion in the MSCI China Index effective May 27, 2021. This recognition positions Burning Rock as the only NGS-based precision oncology company from China included in the current MSCI semi-annual index review. The company's mission emphasizes the use of next generation sequencing technology to enhance precision oncology, with significant activities in therapy selection testing and cancer early detection.
Burning Rock Biotech Limited (NASDAQ: BNR) announced a partnership with Abbisko Therapeutics to develop a companion diagnostic (CDx) assay for ABSK091, aimed at detecting FGFR genetic alterations in urothelial carcinoma patients. Prior studies indicated that ABSK091, an FGFR inhibitor, exhibited safety and preliminary efficacy. Abbisko has received IND approval for ABSK091 from the NMPA and plans to initiate phase Ib/II clinical trials in China. This collaboration aims to leverage next-generation sequencing technology to enhance oncology drug development.
Burning Rock Biotech Limited (NASDAQ: BNR) is set to release its unaudited financial results for Q1 2021 on May 25, 2021, before U.S. market opens. The company will hold a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) the same day to discuss these results. Burning Rock focuses on next generation sequencing (NGS) technology in precision oncology, leading the market in China with over 273,000 completed tests. More details will be available on their investor relations website.
Burning Rock Biotech (NASDAQ: BNR) announced strong results from its liquid biopsy assay, recognized in the FDA-led SEQC2 study published in Nature Biotechnology. The assay achieved superior accuracy, sensitivity, and the lowest false-positive rate among five industry-leading ctDNA assays, highlighting its potential in cancer monitoring. With a sensitivity above 90% at low variant allele frequencies (0.3-0.5%), Burning Rock aims to enhance precision oncology solutions. The assay's high performance positions the company favorably within the rapidly evolving NGS-based ctDNA testing market.
Burning Rock Biotech Limited (NASDAQ: BNR) reported its financial results for Q4 and full year 2020, highlighting a 48.5% revenue increase to RMB131.7 million (US$20.2 million) despite COVID-19 impacts. Full year revenues reached RMB429.9 million (US$65.9 million), a 12.6% rise from 2019. The central laboratory business grew by 22.5% year-over-year. However, the company reported a net loss of RMB156.5 million (US$24.0 million) for Q4 and a total loss of RMB407.2 million (US$62.4 million) for 2020. For 2021, Burning Rock anticipates revenues of approximately RMB610 million (US$93.5 million), indicating 41.9% growth.
Burning Rock Biotech Limited (NASDAQ: BNR) announced plans to release its unaudited fourth quarter and full year 2020 financial results before markets open on March 11, 2021. Following the results, a conference call will be held at 8:00 a.m. ET to discuss financial outcomes. The company focuses on next-generation sequencing for precision oncology, holding a leading market share in China with over 273,000 tests completed. Investors can access the earnings release on the company’s investor relations website.
Burning Rock Biotech Limited (NASDAQ: BNR) announced an exclusive licensing agreement with Oncocyte Corporation (NYSE American: OCX) to introduce the DetermaRx™ test for early stage lung cancer in China. This test identifies high-risk patients who may benefit from chemotherapy post-surgery for non-small-cell lung cancer (NSCLC). Developed from a cohort of 361 patients, the test has shown a significant improvement in 5-year freedom from recurrence rates. The partnership aims to enhance patient outcomes and expand market reach, while also providing financial benefits to both companies.
Burning Rock Biotech Limited (NASDAQ: BNR) announced a secondary public offering of 2,243,000 American Depositary Shares (ADSs) priced at $25.75 each, totaling approximately $57.8 million. The offering comes from selling shareholders, with no proceeds going to the Company. The underwriters, including Morgan Stanley, BofA Securities, and Cowen, have the option to purchase an additional 336,450 ADSs within 30 days. This registration statement was filed with the SEC and became effective on December 3, 2020.
Burning Rock Biotech Limited (NASDAQ: BNR) has filed a registration statement on Form F-1 with the SEC for a public secondary offering of 1,838,000 American Depositary Shares (ADSs). The selling shareholders have also granted underwriters an option for an additional 275,700 ADSs. The company will not receive any proceeds from this offering. Joint bookrunners include Morgan Stanley, BofA Securities, and Cowen.
The offering aims to provide liquidity for current shareholders, but no proceeds will benefit Burning Rock directly.
Burning Rock Biotech Limited (NASDAQ: BNR) reported Q3 2020 financial results, with revenues of RMB123.9 million (US$18.2 million), up 19.4% year-over-year. Central laboratory revenues rose 29.7% to RMB89.9 million, driven by a 27.7% increase in patients tested. In-hospital revenue grew 3.3% to RMB31.7 million. Gross profit was RMB91.6 million, a 17.1% increase, but gross margin declined to 73.9%. Operating expenses surged 93.5% to RMB216.2 million, primarily due to R&D costs, reflecting the company's investment in growth.